Science Explorer Back to mapMap

Most cited papers from ChemoCentryx (United States)

What are the most cited papers from ChemoCentryx (United States)?

The most cited paper from ChemoCentryx (United States) is "A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development" (Jennifer M. Burns, Bretton C. Summers, Yu Wang et al., 2006), with 1,280 citations. Next come "Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis" (632) and "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis" (610).

Showing 50 of 59 papers. Every paper with more than 78 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development Jennifer M. Burns, Bretton C. Summers, Yu Wang et al. · The Journal of Experimental Medicine Open access 28 Aug 2006 1,280
2 Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis Bi‐Sen Ding, Zhongwei Cao, Raphaël Lis et al. · Nature Open access 19 Nov 2013 632
3 Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis David R.W. Jayne, Annette N. Bruchfeld, Lorraine Harper et al. · Journal of the American Society of Nephrology Open access 11 Apr 2017 610
4 A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo Laura R. Saunders et al. · Science Translational Medicine Open access 26 Aug 2015 606
5 Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Charles M. Rudin et al. · The Lancet Oncology Open access 5 Dec 2016 578
6 CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature Zhenhua Miao, Kathryn E. Luker, Bretton C. Summers et al. · Proceedings of the National Academy of Sciences Open access 26 Sep 2007 539
7 Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo Santiago Partida‐Sánchez, Debra A. Cockayne, Simon P. Monard et al. · Nature Medicine Nov 2001 455
8 C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN Hong Xiao, Daniel J. Dairaghi, Jay P. Powers et al. · Journal of the American Society of Nephrology Open access Nov 2013 361
9 CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas Joseph Flores‐Toro, Defang Luo, Adithya Gopinath et al. · Proceedings of the National Academy of Sciences Open access 26 Dec 2019 345
10 Cytomegalovirus encodes a potent α chemokine Mark E.T. Penfold, Daniel J. Dairaghi, Gregory M. Duke et al. · Proceedings of the National Academy of Sciences Open access 17 Aug 1999 336
11 Overcoming hurdles in developing successful drugs targeting chemokine receptors Thomas J. Schall, Amanda E. I. Proudfoot · Nature reviews. Immunology Review 15 Apr 2011 325
12 Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10 Juliet V. Spencer, Kristen M. Lockridge, Peter A. Barry et al. · Journal of Virology Open access Feb 2002 320
13 The Chemokine Receptor CXCR7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects Kirsten Hattermann, Janka Held‐Feindt, Ralph Lucius et al. · Cancer Research 13 Apr 2010 314
14 Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands Brian A. Zabel, Yu Wang, Susanna Lewén et al. · The Journal of Immunology Open access 29 Jul 2009 296
15 The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial Dick de Zeeuw, Pirow J. Bekker, Elena Henkel et al. · The Lancet Diabetes & Endocrinology 9 Aug 2015 281
16 CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity Lillian Cruz‐Orengo, David W. Holman, Denise A. Dorsey et al. · The Journal of Experimental Medicine Open access 7 Feb 2011 230
17 Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK Jennifa Gosling, Daniel J. Dairaghi, Yu Wang et al. · The Journal of Immunology Mar 2000 208
18 Evidence for NK Cell Subsets Based on Chemokine Receptor Expression Robert Berahovich, Nicholas Lai, Zheng Wei et al. · The Journal of Immunology Open access Dec 2006 191
19 HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8 Daniel J. Dairaghi, Rong A. Fan, Brian E. McMaster et al. · Journal of Biological Chemistry Open access Jul 1999 190
20 Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century Samuel A. Williams, Wade C. Anderson, Marianne T. Santaguida et al. · Laboratory Investigation Open access 5 Aug 2013 187
21 Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System Ning Tong, Seth W. Perry, Qing Zhang et al. · The Journal of Immunology Open access Feb 2000 186
22 Proteolytic Activation of Alternative CCR1 Ligands in Inflammation Robert Berahovich, Zhenhua Miao, Yu Wang et al. · The Journal of Immunology Open access Jun 2005 184
23 A review of genetic differences between limited and extensively passaged human cytomegalovirus strains Mark N. Prichard, Mark E.T. Penfold, Greg M. Duke et al. · Reviews in Medical Virology May 2001 176
24 Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation Elektra J. Papadopoulos, Chris Sassetti, Hidehisa Saeki et al. · European Journal of Immunology Open access Aug 1999 170
25 Cancer associated fibroblast FAK regulates malignant cell metabolism Fevzi Demircioglu et al. · Nature Communications Open access 10 Mar 2020 169
26 Cytomegalovirus-encoded β chemokine promotes monocyte-associated viremia in the host Noah Saederup, Yu Lin, Daniel J. Dairaghi et al. · Proceedings of the National Academy of Sciences Open access 14 Sep 1999 164
27 Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease Matthew J. Walters, Yu Wang, Nicholas Lai et al. · Journal of Pharmacology and Experimental Therapeutics 22 Jul 2010 160
28 Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study Pirow J. Bekker, Daniel J. Dairaghi, Lisa C. Seitz et al. · PLoS ONE Open access 21 Oct 2016 152
29 Chemerin Connects Fat to Arterial Contraction Stephanie Wengert Watts, Anne McLaren Dorrance, Mark E.T. Penfold et al. · Arteriosclerosis Thrombosis and Vascular Biology Open access 5 Apr 2013 147
30 Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene Jeffrey Vieira, Thomas J. Schall, Lawrence Corey et al. · Journal of Virology Open access Oct 1998 139
31 Fractalkine receptor expression by T lymphocyte subpopulations andin vivo production of fractalkine in human Arnaud Foussat, Aurore Coulomb L’Herminé, Jennifa Gosling et al. · European Journal of Immunology 2000 138
32 A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease Satish Keshav, Tomáš Vaňásek, Yaron Niv et al. · PLoS ONE Open access 20 Mar 2013 135
33 Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1–PD-L1 Axis Zhi-Chun Ding, Xiaoyun Lu, Miao Yu et al. · Cancer Research Open access 29 Apr 2014 133
34 Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs Kyriacos Costa Nicolaou, Dionisios Vourloumis, Sotirios M. Totokotsopoulos et al. · ChemMedChem 20 Nov 2015 132
35 Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Peter A. Merkel, John L. Niles, Richard Jimenez et al. · ACR Open Rheumatology Open access 31 Oct 2020 127
36 Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells Ping‐Pui Wong et al. · Cell Open access 29 May 2020 112
37 Structural basis of ligand interaction with atypical chemokine receptor 3 Martin B Gustavsson, Liwen Wang, Noortje van Gils et al. · Nature Communications Open access 18 Jan 2017 112
38 CXCR4 and CCR5 Expression Delineates Targets for HIV-1 Disruption of T Cell Differentiation Robert D. Berkowitz, Karen Beckerman, Thomas J. Schall et al. · The Journal of Immunology Open access Oct 1998 112
39 C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment Nissar Ahmad Wani, Mohd Wasim Nasser, Dinesh Kumar Ahirwar et al. · Breast Cancer Research Open access 29 May 2014 110
40 Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3 Michael G. Johnson et al. · Bioorganic & Medicinal Chemistry Letters Open access 7 Apr 2007 107
41 Neuronal expression of fractalkine in the presence and absence of inflammation Wilhelm Schwaeble, Cordula M. Stover, Thomas J. Schall et al. · FEBS Letters Open access 20 Nov 1998 104
42 The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells Brian A. Zabel, Susanna Lewén, Robert Berahovich et al. · Molecular Cancer Open access 14 Jun 2011 102
43 Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial Paul Peter Tak, Andra Rodica Balanescu, Vira Tseluyko et al. · Annals of the Rheumatic Diseases 16 May 2012 101
44 Rapid Uptake and Degradation of CXCL12 Depend on CXCR7 Carboxyl-terminal Serine/Threonine Residues Frauke Hoffmann, Wiebke Müller, Dagmar Schütz et al. · Journal of Biological Chemistry Open access 27 Jun 2012 101
45 Endothelial expression of CXCR 7 and the regulation of systemic CXCL 12 levels Robert Berahovich, Brian A. Zabel, Susanna Lewén et al. · Immunology Open access 12 Oct 2013 98
46 Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan Frank B. Cortazar et al. · Kidney International Reports Open access251 authors 2 Feb 2023 94
47 Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer Nadine S. Jahchan et al. · Cell Reports Open access Jul 2016 90
48 Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats Matthew J. Walters et al. · British Journal of Cancer Open access 14 Jan 2014 90
49 Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias Yu‐Chen Yen, Christopher T. Schafer, Martin B Gustavsson et al. · Science Advances Open access 13 Jul 2022 89
50 Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins Kyriacos Costa Nicolaou, Jun Yin, Debashis Mandal et al. · Journal of the American Chemical Society Feb 2016 89

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.